// App-Quantinova.ai

: Influence of aggressive-variant prostate cancer (AVPC) features on outcome of metastatic hormone-sensitive prostate cancer (mHSPC) treated by chemohormonal therapy (CHT).

Researchers

Presenter

  • Kim Koczka

Principal Investigators

  • James Vanhie

  • Andrea Ibrahim

  • Nedal Bukhari

  • M. Neil Reaume

  • Sandeep R. Sehdev

  • Kylea R. Potvin

  • Lori Sax

  • D. Scott Ernst

  • Michael M. Vickers

  • Christina M. Canil

  • Eric Winquist

  • Michael Ong

Medical Centers

  • The Ottawa Hospital, Ottawa, ON, Canada

  • London Health Sciences Center, London, ON, Canada

  • The Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • University of Western Ontario, London, ON, Canada

  • Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

  • William Osler Health center, Brampton, ON, Canada

  • London Health Sciences Center, London, ON, Canada

  • University of Ottawa, Ottawa, ON, Canada

  • The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada

  • Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • Solute Carrier Family 5 Member 7

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved